WADA Technical Document TD2003IDCR

Similar documents
WADA Technical Document TD2015IDCR

Proposal: criteria for positive identification in LC-MS analysis

All Ions MS/MS: Targeted Screening and Quantitation Using Agilent TOF and Q-TOF LC/MS Systems

Multi-residue analysis of pesticides by GC-HRMS

Mass Spectrometry. Hyphenated Techniques GC-MS LC-MS and MS-MS

FUTURE CONFIRMATORY CRITERIA

Introduction to GC/MS

Overview. Introduction. André Schreiber AB SCIEX Concord, Ontario (Canada)

MassHunter Software Overview

GUIDELINES ON THE USE OF MASS SPECTROMETRY (MS) FOR IDENTIFICATION, CONFIRMATION AND QUANTITATIVE DETERMINATION OF RESIDUES CAC/GL

MassHunter TOF/QTOF Users Meeting

Analytical Technologies and Compound Identification. Daniel L. Norwood, MSPH, PhD SCĪO Analytical Consulting, LLC.

Mass Spectrometry. Ionizer Mass Analyzer Detector

Choosing the metabolomics platform

Applying MRM Spectrum Mode and Library Searching for Enhanced Reporting Confidence in Routine Pesticide Residue Analysis

Yun W. Alelyunas, Mark D. Wrona, Russell J. Mortishire-Smith, Nick Tomczyk, and Paul D. Rainville Waters Corporation, Milford, MA, USA INTRODUCTION

Making Sense of Differences in LCMS Data: Integrated Tools

Quantitative analysis of mitragynine in human urine by high performance liquid chromatography-tandem mass spectrometry

Cerno Bioscience MassWorks: Acquiring Calibration Data on Agilent GC/MSDs

A Rapid Approach to the Confirmation of Drug Metabolites in Preclinical and Clinical Bioanalysis Studies

DRD Trends in Portugal: Updates From Forensic Toxicology Services

LC-MS Based Metabolomics

Key Words Q Exactive, Accela, MetQuest, Mass Frontier, Drug Discovery

MS Interpretation I. Identification of the Molecular Ion

Determination of N-Nitrosamines by USEPA Method 521 using Triple Quadrupole Gas Chromatography Mass Spectrometry

AB SCIEX SelexION Technology Used to Improve Mass Spectral Library Searching Scores by Removal of Isobaric Interferences

Analysis of Opioids Using Isotope Dilution with GCMS-TQ8030 GC/MS/MS. No. GCMS No. SSI-GCMS-1401

Cerno Application Note Extending the Limits of Mass Spectrometry

5Cl-AKB48 and 5Br-AKB48

Automated and accurate component detection using reference mass spectra

Simplified Approaches to Impurity Identification using Accurate Mass UPLC/MS

PesticideScreener. Innovation with Integrity. Comprehensive Pesticide Screening and Quantitation UHR-TOF MS

Quantitative Analysis of Opioids Using a Triple-Quadrupole GC/MS/MS

Agilent MassHunter Quantitative Data Analysis

Analysis of Polar Metabolites using Mass Spectrometry

TANDEM MASS SPECTROSCOPY

Rapid and Accurate Forensics Analysis using High Resolution All Ions MS/MS

Instrumental Analysis. Mass Spectrometry. Lecturer:! Somsak Sirichai

TargetScreener. Innovation with Integrity. A Comprehensive Screening Solution for Forensic Toxicology UHR-TOF MS

Technical Note. Introduction

Agilent MassHunter Profinder: Solving the Challenge of Isotopologue Extraction for Qualitative Flux Analysis

Analyst Software. Peptide and Protein Quantitation Tutorial

SUSPECT AND NON-TARGET SCREENING OF ORGANIC MICROPOLLUTANTS IN WASTEWATER THROUGH THE DEVELOPMENT OF A LC-HRMS BASED WORKFLOW

Analysis of Biomarkers in Crude Oil Using the Agilent 7200 GC/Q-TOF

MS n Analysis With Fast Polarity Switching in the Agilent 1100 Series LC/MSD Trap SL. Application Note. Christine Miller Agilent Technologies

The Emergence of Benchtop Tandem Quadrupole Mass Spectrometers as a Routine Tool in Quantitative GC/MS/MS Applications

[application note] INTRODUCTION EXPERIMENTAL. Specimens. Extraction

Agilent All Ions MS/MS

Analysis of Serum 17-Hydroxyprogesterone, Androstenedione, and Cortisol by UPLC-MS/MS for Clinical Research

Powerful Scan Modes of QTRAP System Technology

Highly Sensitive and Rugged GC/MS/MS Tool

High-Throughput Protein Quantitation Using Multiple Reaction Monitoring

Analytical determination of testosterone in human serum using an Agilent Ultivo Triple Quadrupole LC/MS

New Dynamic MRM Mode Improves Data Quality and Triple Quad Quantification in Complex Analyses

STANDARD OPERATING PROCEDURES SOP: 1828 PAGE: 1 of 14 REV: 0.0 DATE: 05/12/95 ANALYSIS OF METHYL PARATHION IN CARPET SAMPLES BY GC/MS

GAS CHROMATOGRAPHY MASS SPECTROMETRY. Pre-Lab Questions

LC/MS/MS qua ntitation of β-estradiol 17-acetate using an Agilent 6460 Triple Quadrupole LC/MS working in ESI negative ion mode

De Novo Metabolite Chemical Structure Determination. Paul R. West Ph.D. Stemina Biomarker Discovery, Inc.

Agilent TOF Screening & Impurity Profiling Julie Cichelli, PhD LC/MS Small Molecule Workshop Dec 6, 2012

Overview. Introduction. André Schreiber 1 and Yun Yun Zou 1 1 AB SCIEX, Concord, Ontario, Canada

Protein Quantitation II: Multiple Reaction Monitoring. Kelly Ruggles New York University

Impurity Profiling of Pharmaceutical Starting Materials Using Gas Chromatography Coupled with High- Resolution Accurate Mass Spectrometry

Introduction to LC-MS

Quantitation of High Resolution MS Data Using UNIFI: Acquiring and Processing Full Scan or Tof-MRM (Targeted HRMS) Datasets for Quantitative Assays

Analysis of Ethanol and Isotopomers by 240 Quadrupole Ion Trap GC/MS

Plasma Metanephrines and 3-Methoxytyramine by LC/MS/MS Using Agilent SimpliQ WCX SPE, 1290 Infi nity LC, and 6460 Triple Quadrupole LC/MS

An ion source performs the following two functions:

Agilent MassHunter Quantitative Data Analysis

Extend Your Metabolomics Insight!

N-(1-carbamoyl-2-methyl-propyl)-1-(5-chloropentyl)indazole-3- carboxamide

U.S. EPA Method 8270 for multicomponent analyte determination

Identification and Characterization of an Isolated Impurity Fraction: Analysis of an Unknown Degradant Found in Quetiapine Fumarate

Types of Analyzers: Quadrupole: mass filter -part1

Increasing Speed of UHPLC-MS Analysis Using Single-stage Orbitrap Mass Spectrometer

Determination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry

Thermo Scientific LTQ Orbitrap Velos Hybrid FT Mass Spectrometer

Finnigan LCQ Advantage MAX

Maximizing Triple Quadrupole Mass Spectrometry Productivity with the Agilent StreamSelect LC/MS System

Implementing GC-HRAM MS for More Efficient and Effective Routine Pesticide Residues Analysis

HR/AM Targeted Peptide Quantification on a Q Exactive MS: A Unique Combination of High Selectivity, High Sensitivity, and High Throughput

Abstract. Experimental Sample Preparation

Welcome! Course 7: Concepts for LC-MS

Mass Spectrometry. Quantitative Mass Spectrometry Chiral Mass Spectrometry

Using the ACD/MS Manager Software with Agilent 1100 Series LC/MS Systems. Application Note

Quantitation of a target protein in crude samples using targeted peptide quantification by Mass Spectrometry

GUIDELINES ON PERFORMANCE CRITERIA FOR METHODS OF ANALYSIS FOR THE DETERMINATION OF PESTICIDE RESIDUES IN FOOD AND FEED CXG Adopted in 2017.

Optimization of the sample preparation and extraction methodology

Application Note. David A. Weil Zoltan Timar Michael Zumwalt Edgar Naegele. Abstract

Identification and Quantitation of PCB Aroclor Mixtures in a Single Run Using the Agilent 7000B Triple Quadrupole GC/MS

Methyl 1-[(4-fluorophenyl)methyl]indazole-3-carboxylate

This document is a preview generated by EVS

Rapid Screening and Confirmation of Melamine Residues in Milk and Its Products by Liquid Chromatography Tandem Mass Spectrometry

Fundamentals of Mass Spectrometry. Fundamentals of Mass Spectrometry. Learning Objective. Proteomics

Die Nadel im Heuhaufen

Tutorial 2: Analysis of DIA data in Skyline

Protein Quantitation II: Multiple Reaction Monitoring. Kelly Ruggles New York University

Profiling of Diferulates (Plant Cell Wall Cross- Linkers) Using Ultrahigh-performance Liquid. Chromatography-Tandem Mass Spectrometry

Multi-residue GC-MS analysis. Richard Fussell CSL York, UK

for the Novice Mass Spectrometry (^>, John Greaves and John Roboz yc**' CRC Press J Taylor & Francis Group Boca Raton London New York

Forensic and toxicological drug screening using liquid chromatography-tandem mass spectrometry with MS/MS library based identification

Transcription:

IDENTIFICATION CRITERIA FOR QUALITATIVE ASSAYS INCORPORATING CHROMATOGRAPHY AND MASS SPECTROMETRY The appropriate analytical characteristics must be documented for a particular assay. The Laboratory must establish criteria for identification of a compound. Examples of acceptable criteria are: Chromatographic separation For capillary gas chromatography, the retention time (RT) of the analyte shall not differ by more than one (1) percent or ±0.2 minutes (whichever is smaller) from that of the same substance in a spiked urine sample, Reference Collection sample, or Reference Material analyzed contemporaneously. In those cases where shifts in retention can be explained, for example by sample overload, the retention time criteria may be relaxed. For high performance liquid chromatography, the RT of the analyte shall not differ by more than two (2) percent or ±0.4 minutes (whichever is smaller) from that of the same substance in a spiked urine sample, Reference Collection sample, or Reference Material analyzed in the same analytical batch. Mass Spectrometric Detection Full scan mode: A full or partial scan is the preferred approach to identification. A partial scan may begin at an m/z value greater than any abundant ion due to the derivatizing agent or chemical ionization reagent. When a full or partial scan is acquired, all diagnostic ions with a relative abundance greater than 10% in the reference spectrum obtained from a positive control urine, a Reference Collection sample, or a Reference Material must be present in the spectrum of the unknown peak. In addition, the relative abundance of three diagnostic ions shall not differ by more than the amount shown in Table 1 from the relative intensities of the same ions from that of a spiked urine, a Reference Collection sample, or a Reference Material. The relative abundance of the diagnostic ions may be obtained from single or averaged spectra or integration of peak areas of extracted ion profiles. Background subtraction, if applied, should be performed uniformly on all samples analyzed contemporaneously and used to make decisions regarding the presence of a Prohibited Substance or Method, its Metabolite, or Marker. The use of computer-based mass spectral library searching or matching is permitted. The laboratory must establish criteria for acceptance of compound identification based on spectral match quality. Since the match factor of a reverse search does not guarantee identification, all spectral library matches must be reviewed by a qualified scientist. If three diagnostic ions with a relative abundance greater than 5% are not available, a second derivative shall be prepared, or a second ionization or fragmentation technique shall be used. The second derivative should yield different Page 1 of 5

diagnostic ions. The second ionization technique must be based on a different physical principle, i.e., chemical ionization vs. electronic ionization and again should provide different diagnostic ions. It is not acceptable to utilize a technique that changes only the relative abundance of the same mass ions. In any case, a minimum of two diagnostic ions is mandatory in each mass spectrum. Selected Ion Monitoring Mode: In some cases, it may be necessary to monitor selected ions in order to detect the substance at the Minimum Required Performance Limits. When selected ions are monitored, at least three diagnostic ions must be acquired. The relative abundance of a diagnostic ion shall preferably be determined from the peak area or height of integrated selected ion chromatograms. The signal-to-noise ratio of the least intense diagnostic ion must be greater than three to one (3:1). The relative intensities of any of the ions shall not differ by more than the amount in Table 1 from the relative intensities of the same ions acquired from a spiked urine, Reference Collection sample, or Reference Material. For a diagnostic ion with a relative abundance of less than 5% in the reference, the ion must be present in the unknown. The concentration of Prohibited Substance, or its Metabolite, or its Marker should be comparable in the Sample and the spiked urine, Reference Collection sample, or Reference Material. Table 1 Maximum Tolerance Windows for Relative Ion Intensities to Ensure Appropriate Uncertainty in Identification Relative Abundance (% of base peak) EI-GC/MS CI-GC/MS; GC/MS n ; LC/MS ; LC/MS n > 50% ±10% (absolute) ±15% (absolute) 25% to 50% ±20% (relative) ±25% (relative) < 25% ±5% (absolute) ±10% (absolute) If the Laboratory protocol requires three ions to be within a tolerance window to identify a substance, it is not permissible to collect additional ions and select those ion ratios that are within tolerance and ignore others that would not result in meeting identification criteria without a valid explanation. If three diagnostic ions are not available, a second derivative shall be prepared, or a second ionization or fragmentation technique shall be used. The second derivative should yield different diagnostic ions. The second ionization technique must be based on a different physical principle, i.e., chemical ionization vs. electronic ionization and again should provide different diagnostic ions. It is not acceptable to utilize a technique that changes only the relative abundance of the Page 2 of 5

same mass ions. In any case a minimum of two diagnostic ions must be present in each mass spectrum. Tandem mass spectrometric (MS n ) detection: Tandem mass spectrometry data can be acquired in either the full scan or selected reaction monitoring (SRM) mode. The combination of mass selection of the precursor ion followed by a potentially unique collision-induced dissociation and mass selection or scanning of the product ion gives tandem mass spectrometry increased specificity. Collision conditions should be selected to ensure that the precursor ion is present in the MS/MS scan or SRM acquisition. In some cases, the combination of a single precursor-product ion pair may be sufficiently unique to be definitive. When monitoring one precursor ion to yield one product ion, the mass resolution of the first mass analyzer should be set to unity. When monitoring more than one product ion, the relative intensities of any of the ions shall not differ by more than the amount in Table 1 from the relative intensities of the same ions acquired from a spiked urine, Reference Collection sample, or Reference Material analyzed contemporaneously. The signal-to-noise of the least intense diagnostic ion must be greater than three-to-one (3:1). The relative abundance of a diagnostic ion shall preferably be determined from the peak area or height of integrated selected ion chromatograms. For a diagnostic ion with a relative abundance of less than 5% in the reference, the ion must be present in the unknown. If unique diagnostic product ion(s) are not available, a second derivative shall be prepared, or a second ionization or fragmentation technique shall be used. The second derivative should yield different precursor and/or product ions. The second ionization technique may use a different chemical ionization reagent, but should provide different precursor or product ions. It is not acceptable to utilize a technique that changes only the relative abundance of the same mass ions. Estimation of concentration The concentration may be estimated by any of the above techniques by taking the ratio of the peak height (or peak area) obtained at the retention time for the analyte of interest compared to that obtained from an internal standard. An appropriately deuterated internal standard is preferred but not required. The peak height (or peak area) ratio may then be compared to a standard or positive control urine. The use of a single ion at the appropriate mass-to-charge ratio (e.g. m/z 405 for 19-norandrosterone di-tms derivative) taken from an extracted ion chromatogram or from a selected ion monitoring chromatogram is sufficient for the estimation of concentration. Additional ions must be used for meeting identification criteria. Definitions Page 3 of 5

Diagnostic ion(s): Molecular ion or fragment ions whose presence and abundance are characteristic of the substance and thereby may assist in its identification. A second ion belonging to the same isotopic cluster may also be used as diagnostic only when the peculiarity of the atomic composition of the fragment so justifies (e.g. presence of Cl, Br, or other elements with abundant isotopic ions). High resolution mass spectrometry (HRMS): For the purposes of the International Standards for Laboratories, HRMS is defined as mass spectrometry at a resolving power (10 % valley definition) in excess of 3,000. Low resolution mass spectrometry (LRMS): LRMS is defined as mass spectrometry at a resolving power (10 % valley definition) lower than 3,000. Relative abundance (mass spectrometry): The abundance of a particular ion relative to the most abundant ion monitored expressed as a percentage. Maximum difference in relative abundance: The maximum permitted difference between the relative abundance of a particular ion obtained from the Sample and that obtained from the positive control urine. This may be expressed in ABSOLUTE or RELATIVE terms. Absolute difference: Calculated by subtracting the stated percentage from the relative abundance obtained for the studied ion from the positive control urine or Reference Material. For example, if the relative abundance of an ion in the chromatographic peak of interest in the positive control urine or Reference Material is measured as 20%, then the observed relative abundance for the same ion in the peak of interest in the unknown urine sample would be required to be in the range of 15-25% (20% ± 5%) for the ion to contribute to an acceptable identification. Relative difference: Calculated by multiplying the stated percentage by the relative abundance obtained for the studied ion from the positive control urine or Reference Material. For example, if the relative abundance of an ion in the chromatographic peak of interest in the positive control urine or Reference Material appears as 30 % and the stated maximum permitted difference is 20 % (relative), then the observed relative abundance for the same ion in the peak of interest in the unknown urine sample would be required to be in the range of 24-36% (30% ± (30 x 20 %)) for the ion to contribute to an acceptable identification. Scan: Acquisition of ions of a continuous range of m/z values. Selected ion monitoring (SIM): Acquisition of ions of one or more pre-determined discrete m/z values for specified dwell times. Signal-to-Noise Ratio: Magnitude of the instrument response to the analyte (signal) relative to the magnitude of the background (noise). Page 4 of 5

Tandem mass spectrometry (MS/MS or MS n ): A technique in which a precursor ion is isolated in a mass analyzer, fragmented by collision with a collision gas, and the product ions collected in a second mass analyzer. This process can be applied multiple times, each application being reflected in the n exponent. The technique may be accomplished either in space (e.g. triple quadrupole MS) or in time (e.g. ion trap MS) Page 5 of 5